Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | DDX3X | O00571 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235491 | 0.88 | HRH3 (0.48) | HRH3MCHR1MEN1KMT2ANAMPT | |
| SCHEMBL4238075 | 0.88 | HRH3 (0.44) | HRH3DDX3XMEN1KMT2AMAOA | |
| SCHEMBL4236986 | 0.87 | MCHR1 (0.43) | HRH3MCHR1NAMPT | |
| SCHEMBL4233740 | 0.85 | MCHR1 (0.39) | HRH3DDX3XMCHR1MEN1KMT2A | |
| SCHEMBL4233415 | 0.85 | MCHR1 (0.50) | HRH3MCHR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4236318 | 0.85 | MCHR1 (0.39) | HRH3DDX3XMCHR1MEN1KMT2A | |
| SCHEMBL4231873 | 0.85 | CHRM3 (0.43) | HRH3DDX3XMCHR1MEN1KMT2A | |
| SCHEMBL4690069 | 0.84 | SMN1; SMN2 (0.41) | HRH3DDX3XMCHR1MAOAMAOB | |
| SCHEMBL4235464 | 0.84 | MCHR1 (0.44) | HRH3MCHR1NAMPT | |
| SCHEMBL4236380 | 0.83 | HRH3 (0.47) | HRH3MEN1KMT2ANAMPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | claimed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885DDX3X 3915/4885MCHR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.